Familial combined hyperlipidemia: From molecular insights to tailored therapy

Current Opinion in Lipidology

Volumn 25, Issue 3, 2014, Pages 176-182

  Van Greevenbroek, Marleen M J ^a   Stalenhoef, Anton F H ^b   De Graaf, Jacqueline ^b   Brouwers, Martijn C G J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cause; comorbidities; familial combined hyperlipidemia; genetics; treatment

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIPOMERSEN; PHOSPHOLIPID TRANSFER PROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE; SIMVASTATIN; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; CARRIER PROTEIN; PCSK9 PROTEIN, HUMAN; SLC25A40 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; DYSLIPIDEMIA; EXOME; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FATTY LIVER; GENE; GENE EXPRESSION; GENE REPLICATION; GENE SEQUENCE; GENETIC LINKAGE; HUMAN; LASS4 GENE; LIVER BIOPSY; LIVER CELL CULTURE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SLC25A40 GENE; GENE EXPRESSION REGULATION; GENETICS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIVER; METABOLISM; PATHOLOGY;

ADIPOCYTES; GENE EXPRESSION REGULATION; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIVER; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84900510344     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000068     Document Type: Review

References (39)

1. Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorde r, combined hyperlipidemia. J Clin Invest 1973; 52:1544-1568.
2. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyc eridemia: A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108:519-523.
3. Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109:2980-2985.
4. Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia: Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32:71-7 3.
5. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2013.
6. B rouwers MC, van Greevenbroek MM, Stehouwer CD, et al. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol 2012; 8:352-362. Comprehensive report on the genetics of FCHL.
7. van der Kallen CJ, Voors-Pette C, de Bruin TW. Abdominal obesity and expression of familial combined hyperlipidemia. Obes Res 2004; 12:2054-2061.
8. Auer S,Hahne P,Soyal SM,et al, Potential role of upstream stimulatory factor 1 gene variant in familial combined hyperlipidemia and related disorders. Arterioscler Thromb Vasc Biol, 2012, 32, 1535-1544.
9. Rosenthal EA, Ranchalis J, Crosslin DR, et al. Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia. Am J Hum Genet 2013; 93:1035-1045.
10. Rosenthal EA, Ronald J, Rothstein J, et al. Linkage and association of phospholipid transfer protein activity to LASS4. J Lipid Res 2011; 52: 1837 -1846.
11. Brouwers MC, van Greevenbroek MM, Troutt JS, et al. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia. Clin Sci (Lond) 2011; 121:397-403.
12. Brou wers MC, Isaacs A, Konrad RJ et al. No linkage for circulating proprotein convertase subtilisin kexin type 9 in 32 familial combined hyperlipidemia pedigrees. [electronic response to Chernogubova et al. Common and lowfrequency genetic var i ants in the PCSK9 locus influencing circulating PCSK9 levels]. Atvb.ahajournals.org 2012. http://atvb.ahajournals.org/cgi/ eletters/ATVBAHA.111.240549 2012 [Accessed 30 January 2014].
13. Chernogubova E, Stra wbridge R, Mahdessian H, et al. Common and lowfrequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol 2012; 32:1526-1534.
14. Baila-Rueda L, Mateo-Gallego R, Jarauta E, et al. Bile acid synthesis precursors in familial combined hyperlipidemia: The oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol. Biochem Biophys Res Commun 2014; Online Jan 6 2014 DOI: 10. 1016/j.bbrc.2013.12.131.
15. Lupattelli G, Siepi D, De Vuono S, et al. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sci 2012; 90:846-850.
16. van Himbergen TM, Otokozawa S, Matthan NR, et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler Thromb Vasc Biol 2010; 30:113-1 20.
17. Brouwers MC, Konrad RJ, van Himbergen TM, et al. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutr Meta b Cardiovasc Dis 2013; 23:1115-1121.
18. Arner P, Bernard S, Salehpour M, et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature 2011; 478:110-113.
19. Stubiger G, Aldover-Macasaet E, Bicker W, et al. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS. Atherosclerosis 2012; 224:177-186.
20. Jarauta E, Mateo-Gallego R, Gilabert R, et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis 2012; 22:591-597.
21. van Greevenbroek MM, Ghosh S, van der Kallen CJ, et al. Up-regulation of the complement system in subcutaneous adipocytes from nonobese, hypertri glyceridemic subjects is associated with adipocyte insulin resistance. J Clin Endocrinol Metab 2012; 97:4742-4752.
22. Horswell SD, Fryer LG, Hutchison CE, et al. CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. J Lipid Res 2013; 54: 3491-3505.
23. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101:2777-2782.
24. Brouwers MC, van d er Kallen CJ, Schaper NC, et al. Five-year incidence of type 2 diabetes mellitus in patients with familial combined hyperlipidaemia. Neth J Med 2010; 68:163-167.
25. CannonCP, GiuglianoRP, BlazingMA, et al.Rationale and design of IMPROVEIT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156:826-832.
26. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the Eur opean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
27. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
28. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
29. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, prespecified muscle and liver outcomes, and reaso ns for stopping study treatment. Eur Heart J, 2013, 34, 1279-1291.
30. Brouwers MC, de Graaf J, van GreevenbroekMM, et al. Novel drugs in familial combined hyperlipidemia: Lessons from type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21:530-538.
31. Brouwers MC, Stehouwer CD. Niacin in cardiovascular patients receiving statins. N Engl J Med 2012; 366:1255; author reply 1255-1256.
32. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-742.
33. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380:565-571.
34. Brouwers MC, van Greevenbroek MM, Bilderbeek-Beckers MA, et al. Fatty liver: Based identification of two distinct hypertriglyceridemic subgroups in familial combined hyperlipidemia. Metabolism 2007; 56:1311-1317. 35. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: Normolipemic subjects, familial hypertriglyceridemia and familial combined hyper lipidemia. Metabolism 1981; 30:856-868.
35. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: Normolipemic subjects, familial hypertriglyceridemia and familial combined hyper lipidemia. Metabolism 1981; 30:856-868
36. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51:1057-1062.
37. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-2292.
38. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891 - 1900. Phase II interventional study showing that PCSK9-lowering therapy has a substantial effect on LDL cholesterol levels, even on top of statin therapy.
39. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007; 18:304-309.